Scarica l'app Stockscreener
19.63
0.71%
-0.14
Dopo l'orario di chiusura:
19.24
-0.39
-1.99%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$19.77
Aprire:
$19.73
Volume 24 ore:
674.43K
Relative Volume:
0.91
Capitalizzazione di mercato:
$1.08B
Reddito:
$199.89M
Utile/perdita netta:
$52.48M
Rapporto P/E:
23.09
EPS:
0.85
Flusso di cassa netto:
$61.15M
1 W Prestazione:
-0.71%
1M Prestazione:
+49.39%
6M Prestazione:
+158.97%
1 anno Prestazione:
+26.73%
Intervallo 1D:
$18.80
$19.88
Intervallo di 1 settimana:
$18.80
$20.45
Portata 52W:
$5.35
$20.45
Stoke Therapeutics Inc Stock (STOK) Company Profile
Nome
Stoke Therapeutics Inc
Settore
Industria
Telefono
781-430-8200
Indirizzo
45 WIGGINS AVENUE, BEDFORD, MA
Confronta STOK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
19.63 | 1.07B | 199.89M | 52.48M | 61.15M | 0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-18 | Iniziato | Jefferies | Buy |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-03-26 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-07-25 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Ripresa | Canaccord Genuity | Buy |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-10-24 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Iniziato | Jefferies | Buy |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-11-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Iniziato | UBS | Neutral |
| 2021-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-15 | Ripresa | H.C. Wainwright | Buy |
| 2020-12-11 | Reiterato | Needham | Buy |
| 2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-09-29 | Iniziato | Needham | Buy |
| 2019-12-18 | Iniziato | Wedbush | Outperform |
| 2019-11-12 | Iniziato | BTIG Research | Buy |
| 2019-10-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-15 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Credit Suisse | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
Stoke Therapeutics' Insider Sales: A Cautionary Tale or a Sign of Strength? - AInvest
Assessing Insider Selling Trends at Stoke Therapeutics (STOK): Liquidity Moves or Loss of Confidence? - AInvest
Market reaction to Stoke Therapeutics Inc.’s recent newsJuly 2025 News Drivers & AI Forecast Swing Trade Picks - Newser
Will Stoke Therapeutics Inc. benefit from rate cutsQuarterly Profit Summary & Free Technical Confirmation Trade Alerts - khodrobank.com
Sector ETF performance correlation with Stoke Therapeutics Inc.Dollar Strength & Weekly Top Performers Watchlists - Newser
Volume spikes in Stoke Therapeutics Inc. stock – what they meanDividend Hike & Low Risk Growth Stock Ideas - Newser
Analyzing drawdowns of Stoke Therapeutics Inc. with statistical tools2025 Trading Recap & Growth Oriented Trade Recommendations - Newser
What analysts say about Stoke Therapeutics Inc. stockJuly 2025 Sentiment & Precise Swing Trade Entry Alerts - khodrobank.com
Stoke Therapeutics shares fall 2.40% premarket after presenting data from Phase 1/2a and open-label extension studies of zorevunersen. - AInvest
What does recent volatility data suggest for Stoke Therapeutics Inc.2025 Earnings Surprises & Trade Opportunity Analysis Reports - Newser
Is Stoke Therapeutics Inc. still worth holding after the dipJuly 2025 Levels & Technical Entry and Exit Tips - Newser
Can a trend reversal in Stoke Therapeutics Inc. lead to recoveryIndex Update & Risk Controlled Swing Trade Alerts - Newser
Key metrics from Stoke Therapeutics Inc.’s quarterly dataPrice Action & Weekly Market Pulse Alerts - Newser
What’s next for Stoke Therapeutics Inc. stock pricePortfolio Risk Summary & Stock Portfolio Risk Management - Newser
What are the risks of holding Stoke Therapeutics Inc.Quarterly Profit Summary & Long-Term Growth Portfolio Plans - khodrobank.com
Is Stoke Therapeutics Inc. stock ready for a breakoutJuly 2025 Update & Community Supported Trade Ideas - Newser
Relative strength of Stoke Therapeutics Inc. in sector analysis2025 Bull vs Bear & Daily Market Momentum Tracking - Newser
Institutional scanner results for Stoke Therapeutics Inc.Portfolio Gains Report & Weekly Market Pulse Alerts - Newser
Why is Stoke Therapeutics Inc. stock going upWeekly Stock Recap & Low Volatility Stock Suggestions - khodrobank.com
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome | BIIB - GuruFocus
Biogen and Stoke Therapeutics Announce Three-Year Results Supporting Zorevunersen's Promise for Dravet Syndrome Treatment - Quiver Quantitative
Biogen and Stoke Therapeutics Present Data at the 36th - GlobeNewswire
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome - Biogen
Biogen Inc. - Via Ritzau
Can volume confirm reversal in Stoke Therapeutics Inc.Trade Entry Summary & Daily Growth Stock Investment Tips - Newser
Statistical indicators supporting Stoke Therapeutics Inc.’s strength2025 Analyst Calls & Reliable Trade Execution Plans - Newser
Applying Wyckoff theory to Stoke Therapeutics Inc. stockJuly 2025 Price Swings & Accurate Trade Setup Notifications - Newser
Using economic indicators to assess Stoke Therapeutics Inc. potentialJuly 2025 Setups & Safe Swing Trade Setup Alerts - Newser
Comparing Stoke Therapeutics Inc. in custom built stock radarsBear Alert & Real-Time Volume Surge Alerts - Newser
Will Stoke Therapeutics Inc. stock go up in YEARProfit Target & Step-by-Step Swing Trade Plans - khodrobank.com
What’s the analyst consensus on Stoke Therapeutics Inc.July 2025 Review & Stock Portfolio Risk Management - khodrobank.com
Earnings visualization tools for Stoke Therapeutics Inc.Weekly Market Outlook & Verified Swing Trading Watchlists - Newser
Is Stoke Therapeutics Inc. stock risky to hold nowJuly 2025 Review & Fast Gain Stock Trading Tips - khodrobank.com
Chart based analysis of Stoke Therapeutics Inc. trendsMarket Risk Analysis & Growth Oriented Trade Recommendations - Newser
What MACD and RSI say about Stoke Therapeutics Inc.Day Trade & Daily Profit Maximizing Tips - Newser
Will breakout in Stoke Therapeutics Inc. lead to full recoveryWeekly Profit Summary & Fast Gaining Stock Reports - Newser
Earnings visualization tools for Stoke Therapeutics Inc2025 Price Targets & High Accuracy Trade Alerts - Newser
Stoke Therapeutics Inc. recovery potential after sell off2025 Macro Impact & Low Drawdown Momentum Ideas - Newser
How to use Fibonacci retracement on Stoke Therapeutics Inc.Quarterly Portfolio Summary & Reliable Intraday Trade Plans - Newser
Stoke Therapeutics Inc Azioni (STOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Stoke Therapeutics Inc Azioni (STOK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kaye Edward M. MD | Director |
Sep 03 '25 |
Sale |
20.13 |
45,996 |
925,858 |
91,585 |
| Kaye Edward M. MD | Director |
Sep 02 '25 |
Sale |
20.14 |
14,860 |
299,260 |
137,581 |
| Kaye Edward M. MD | Director |
Aug 29 '25 |
Sale |
20.00 |
1,029 |
20,580 |
152,441 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Sep 02 '25 |
Option Exercise |
7.07 |
9,150 |
64,690 |
33,098 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Aug 29 '25 |
Option Exercise |
7.07 |
850 |
6,010 |
24,798 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Sep 02 '25 |
Sale |
20.14 |
14,922 |
300,492 |
18,176 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Sep 03 '25 |
Sale |
20.07 |
6,345 |
127,317 |
11,831 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Aug 29 '25 |
Sale |
20.00 |
850 |
17,000 |
23,948 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):